Conversion surgery for recurrent hepatic angiosarcoma after systemic chemotherapy with paclitaxel

[1]  K. Moon,et al.  Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who Received Systemic Treatment , 2021, Cancer research and treatment.

[2]  T. Chen,et al.  The treatment landscape of advanced angiosarcoma in Asia—A multi‐national collaboration from the Asian Sarcoma Consortium , 2021, Cancer science.

[3]  Shaotao Jiang,et al.  Surgery and chemotherapy improve the prognosis of primary hepatic angiosarcoma: A retrospective study based on Propensity score matched survival analysis. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  H. Lang,et al.  Surgical therapy of primary hepatic angiosarcoma , 2019, BMC Surgery.

[5]  X. Ren,et al.  Primary hepatic angiosarcoma and potential treatment options , 2014, Journal of gastroenterology and hepatology.

[6]  R. Danesi,et al.  The pharmacological bases of the antiangiogenic activity of paclitaxel , 2013, Angiogenesis.

[7]  Yu-xin Jiang,et al.  Contrast-enhanced ultrasound study of primary hepatic angiosarcoma: a pitfall of non-enhancement. , 2012, European journal of radiology.

[8]  Qiang Li,et al.  Primary hepatic angiosarcoma: A retrospective analysis of 6 cases , 2012, Journal of digestive diseases.

[9]  How-Ran Guo,et al.  Arsenic, vinyl chloride, viral hepatitis, and hepatic angiosarcoma: A hospital-based study and review of literature in Taiwan , 2011, BMC gastroenterology.

[10]  M. Koch,et al.  Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. , 2011, Surgery.

[11]  Y. N. Park,et al.  Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Blay,et al.  Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Blay,et al.  Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. D'Angelica,et al.  Management of primary liver sarcomas , 2007, Cancer.

[15]  B. Brkljačić,et al.  Two cases of lethal complications following ultrasound-guided percutaneous fine-needle biopsy of the liver , 1996, CardioVascular and Interventional Radiology.

[16]  F. Boccardo,et al.  Secondary breast angiosarcoma: lethal response to anti-angiogenic therapy with paclitaxel chemotherapy. A case report. , 2006, Anticancer research.

[17]  P. Canney,et al.  Radiation-induced angiosarcoma of the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy. , 2006, Breast.

[18]  K. Skubitz,et al.  Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma , 2005, Cancer.

[19]  C. Antonescu,et al.  A 14‐Year Retrospective Review of Angiosarcoma: Clinical Characteristics, Prognostic Factors, and Treatment Outcomes with Surgery and Chemotherapy , 2005, Cancer journal.

[20]  C. Pestoni,et al.  Early detection of cutaneous angiosarcoma of the face and scalp and treatment with placitaxel , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  K. Takehara,et al.  Weekly low‐dose docetaxel in the treatment of lung metastases from angiosarcoma of the head , 2005, The British journal of dermatology.

[22]  E. Molina,et al.  Clinical Manifestations of Primary Hepatic Angiosarcoma , 2003, Digestive Diseases and Sciences.

[23]  M. Erkan,et al.  Five years and 4 months of recurrence-free survival in hepatic angiosarcoma. , 2003, Journal of hepato-biliary-pancreatic surgery.

[24]  D. V. van Thiel,et al.  Mesenchymal tumors of the liver. , 2001, Clinics in liver disease.

[25]  O. Grandas,et al.  Hepatic Angiosarcoma: Long-Term Survival after Complete Surgical Removal , 2000, The American surgeon.

[26]  G. Schwartz,et al.  Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face , 1999, Cancer.

[27]  I. Kleinschmidt,et al.  Angiosarcoma of the liver in Great Britain in proximity to vinyl chloride sites. , 1997, Occupational and environmental medicine.

[28]  G. Viale,et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  T. Nakashima,et al.  Pathomorphologic characteristics of 102 cases of thorotrast‐related hepatocellular carcinoma, cholangiocarcinoma, and hepatic angiosarcoma , 1988, Cancer.

[30]  J. Creech,et al.  Clinical and morphologic features of hepatic angiosarcoma in vinyl chloride workers , 1976, Cancer.